Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02877381 · ClinicalTrials.gov registry record · Phase 4
Tranexamic Acid in Revision Total Joint Arthroplasty
A Phase 4 study, sponsored by Rush University Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 175
- Enrollment target
NCT02877381 is a Phase 4 study that has completed, run by Rush University Medical Center. The registered enrollment target is 175 participants.
The verdict
NCT02877381, a Phase 4 study, has completed, sponsored by Rush University Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 175 participants
- Enrollment target
Study Summary
To determine the optimal dosing regimen and route of administration of tranexamic acid (TXA) \[single dose intravenous (IV), double dose intravenous, intravenous + topical, and oral repeated dosing\] to minimize post-operative blood loss and transfusion requirements following revision total knee arthroplasty (RTKA).
Interventions
- PROCEDURE Revision Total Knee Arthroplasty (TKA)
- PROCEDURE Revision Total Hip Arthroplasty (THA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2016-04 |
| Est. Completion | 2019-08-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02877381
The ClinicalTrials.gov registry entry for NCT02877381 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Revision Total Knee Arthroplasty (TKA) is the first listed.
NCT02877381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02877381 about?
NCT02877381 is a clinical study titled "Tranexamic Acid in Revision Total Joint Arthroplasty". To determine the optimal dosing regimen and route of administration of tranexamic acid (TXA) \[single dose intravenous (IV), double dose intravenous, intravenous + topical, and oral repeated dosing\] to minimize post-operative blood loss and transfusion requirements following revision total knee art...
What is the current status of trial NCT02877381?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 175 participants. The study started on 2016-04. Estimated completion is 2019-08-01.
What interventions are being tested in trial NCT02877381?
The interventions under investigation include: Revision Total Knee Arthroplasty (TKA) (PROCEDURE), Revision Total Hip Arthroplasty (THA) (PROCEDURE).
Who is sponsoring clinical trial NCT02877381?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.